Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of hemiparkinsonian rats

Glover, 2005, Towards safe, non-viral therapeutic gene expression in humans, Nat. Rev. Genet., 6, 299, 10.1038/nrg1577 Pack, 2005, Design and development of polymers for gene delivery, Nat. Rev. Drug Discovery, 4, 581, 10.1038/nrd1775 Alvarez-Maya, 2001, In vivo gene transfer to dopamine neurons of rat substantia nigra via the high-affinity neurotensin receptor, Mol. Med., 7, 186, 10.1007/BF03401952 Navarro-Quiroga, 2002, Improved neurotensin-vector-mediated gene transfer by the coupling of hemagglutinin HA2 fusogenic peptide and Vp1 SV40 nuclear localization signal, Brain Res. Mol. Brain Res., 105, 86, 10.1016/S0169-328X(02)00396-0 Arango-Rodriguez, M.L., et al. Biophysical characteristics of neurotensin polyplex for in vitro and in vivo gene transfection. Biochim. Biophys. Acta Jeong, 2003, Synthesis and characterization of poly(l-lysine)-g-poly(d,l-lactic-co-glycolic acid) biodegradable micelles, J. Biomater. Sci. Polym. Ed., 14, 1, 10.1163/15685620360511100 Martinez-Fong, 1999, Neurotensin-SPDP-poly-l-lysine conjugate: a nonviral vector for targeted gene delivery to neural cells, Brain Res. Mol. Brain Res., 69, 249, 10.1016/S0169-328X(99)00114-X Sacchetti, 1999, Characterization of the 5′-flanking region of the human dopamine transporter gene, Brain Res. Mol. Brain Res., 74, 167, 10.1016/S0169-328X(99)00275-2 Lin, 1993, GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons, Science, 260, 1130, 10.1126/science.8493557 Airaksinen, 2002, The GDNF family: signalling, biological functions and therapeutic value, Nat. Rev. Neurosci., 3, 383, 10.1038/nrn812 Ericson, 2005, Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease, Eur. J. Neurosci., 22, 2755, 10.1111/j.1460-9568.2005.04503.x Gill, 2003, Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease, Nat. Med., 9, 589, 10.1038/nm850 Slevin, 2005, Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputamenal infusion of glial cell line-derived neurotrophic factor, J. Neurosurg., 102, 216, 10.3171/jns.2005.102.2.0216 Patel, 2005, Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study, Ann. Neurol., 57, 298, 10.1002/ana.20374 Bjorklund, 2000, Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model, Brain Res., 886, 82, 10.1016/S0006-8993(00)02915-2 Palfi, 2002, Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration, J. Neurosci., 22, 4942, 10.1523/JNEUROSCI.22-12-04942.2002 Wang, 2002, Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease, Gene Ther., 9, 381, 10.1038/sj.gt.3301682 Georgievska, 2004, Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time-and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system, J. Neurosci., 24, 6437, 10.1523/JNEUROSCI.1122-04.2004 Do Thi, 2004, Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease, Gene Ther., 11, 746, 10.1038/sj.gt.3302222 Eslamboli, 2005, Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease, J. Neurosci., 25, 769, 10.1523/JNEUROSCI.4421-04.2005 Li, 2006, Viral-mediated temporally controlled dopamine production in a rat model of Parkinson disease, Mol. Ther., 13, 160, 10.1016/j.ymthe.2005.08.009 Ziady, 2004, Defining strategies to extend duration of gene expression from targeted compacted DNA vectors, Gene Ther., 11, 1378, 10.1038/sj.gt.3302299 Bryans, 1992, Vector methylation inhibits transcription from the SV40 early promoter, FEBS Lett., 309, 97, 10.1016/0014-5793(92)80748-6 Brooks, 2004, Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle, J. Gene Med., 6, 395, 10.1002/jgm.516 Grimm, 1998, Analysis of the human GDNF gene reveals an inducible promoter, three exons, a triplet repeat within the 3′-UTR and alternative splice products, Hum. Mol. Genet., 7, 1873, 10.1093/hmg/7.12.1873 Moretto, 1996, Expression and regulation of glial-cell-line-derived neurotrophic factor (GDNF) mRNA in human astrocytes in vitro, Cell Tissue Res., 286, 257, 10.1007/s004410050695 Jing, 1996, GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF, Cell, 85, 1113, 10.1016/S0092-8674(00)81311-2 Wordinger, 2003, Cells of the human optic nerve head express glial cell line-derived neurotrophic factor (GDNF) and the GDNF receptor complex, Mol. Vision, 9, 249 Kirik, 1998, Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat, Exp. Neurol., 152, 259, 10.1006/exnr.1998.6848 Marshall, 1977, Supersensitivity to apomorphine following destruction of the ascending dopamine neurons: quantification using the rotational model, Eur. J. Pharmacol., 41, 361, 10.1016/0014-2999(77)90256-4 Hefti, 1980, Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization, Brain Res., 195, 123, 10.1016/0006-8993(80)90871-9 Hudson, 1993, Correlation of apomorphine-and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats, Brain Res., 626, 167, 10.1016/0006-8993(93)90576-9 Lee, 1996, Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat, Neuroscience, 72, 641, 10.1016/0306-4522(95)00571-4 Deumens, 2002, Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway, Exp. Neurol., 175, 303, 10.1006/exnr.2002.7891 Checler, 1988, Neurotensin metabolism in various tissues of central and peripheral origins: ubiquitous involvement of a novel neurotensin degrading metalloendopeptidase, Biochimie, 70, 75, 10.1016/0300-9084(88)90161-7 Laurent, 1999, Uptake by rat liver and intracellular fate of plasmid DNA complexed with poly-l-lysine or poly-d-lysine, FEBS Lett., 443, 61, 10.1016/S0014-5793(98)01677-9 Symonds, 2005, Low and high molecular weight poly(l-lysine)s/poly(l-lysine)–DNA complexes initiate mitochondrial-mediated apoptosis differently, FEBS Lett., 579, 6191, 10.1016/j.febslet.2005.09.092 Georgievska, 2002, Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer, Exp. Neurol., 177, 461, 10.1006/exnr.2002.8006 Rosenblad, 2003, Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system, Eur. J. Neurosci., 17, 260, 10.1046/j.1460-9568.2003.02456.x Toniatti, 2004, Gene therapy progress and prospects: transcription regulatory systems, Gene Ther., 11, 649, 10.1038/sj.gt.3302251 Martinez-Fong, 2000, Synthesis of a non-viral vector for gene transfer via the high-affinity neurotensin receptor, Brain Res. Brain Res. Protoc., 6, 13, 10.1016/S1385-299X(00)00032-5 Mizushima, 1990, Pef-Bos, a powerful mammalian expression vector, Nucleic Acids Res., 18, 5322, 10.1093/nar/18.17.5322 Meng, 2000, Regulation of cell fate decision of undifferentiated spermatogonia by GDNF, Science, 287, 1489, 10.1126/science.287.5457.1489 Paxinos, 1986 Garcia-Ramirez, 2004, Intranigral injection of the H3 agonist immepip and systemic apomorphine elicit ipsilateral turning behaviour in naive rats, but reduce contralateral turning in hemiparkinsonian rats, Behav. Brain Res., 154, 409, 10.1016/j.bbr.2004.03.007 Martinez-Fong, 1992, NMDA receptor mediates dopamine release in the striatum of unanesthetized rats as measured by brain microdialysis, Brain Res., 595, 309, 10.1016/0006-8993(92)91065-M Flores, 1999, Expression of dopamine receptors in the subthalamic nucleus of the rat: characterization using reverse transcriptase polymerase chain reaction and autoradiography, Neuroscience, 91, 549, 10.1016/S0306-4522(98)00633-2 Gonzalez-Barrios, 2002, Nitric oxide and nitric oxide synthases in the fetal cerebral cortex of rats following transient uteroplacental ischemia, Brain Res., 945, 114, 10.1016/S0006-8993(02)02746-4 Segovia, 1998, Differentiation-dependent expression of transgenes in engineered astrocyte cell lines, Neurosci. Lett., 242, 172, 10.1016/S0304-3940(98)00042-1 Garcia-Tovar, 2001, Biochemical and histochemical analysis of 71 kDa dystrophin isoform (Dp71f) in rat brain, Acta Histochem., 103, 209, 10.1078/0065-1281-00591